Jonasch E, Walker CL, Rathmell WK. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality. Nat Rev Nephrol. 2021;17(4):245–61.

Article  CAS  PubMed  Google Scholar 

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, Heng DY, Larkin J, Ficarra V. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3:17009.

Article  PubMed  PubMed Central  Google Scholar 

Li Y, Lih TM, Dhanasekaran SM, Mannan R, Chen L, Cieslik M, Wu Y, Lu RJ, Clark DJ, Kolodziejczak I, et al. Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness. Cancer Cell. 2023;41(1):139–e163117.

Article  CAS  PubMed  Google Scholar 

Xing T, He H. Epigenomics of clear cell renal cell carcinoma: mechanisms and potential use in molecular pathology. Chin J Cancer Res. 2016;28(1):80–91.

CAS  PubMed  PubMed Central  Google Scholar 

Masuda T, Tanaka N, Takamatsu K, Hakozaki K, Takahashi R, Anno T, Kufukihara R, Shojo K, Mikami S, Shinojima T et al. Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer. J Immunother Cancer 2022, 10(3).

Cinque A, Minnei R, Floris M, Trevisani F. The clinical and molecular features in the VHL renal cancers; close or distant relatives with sporadic Clear Cell Renal Cell Carcinoma? Cancers (Basel) 2022, 14(21).

Rysz J, Franczyk B, Lawinski J, Gluba-Brzozka A. Characteristics of Clear Cell Papillary Renal Cell Carcinoma (ccpRCC). Int J Mol Sci 2021, 23(1).

Wang B, Song Q, Wei Y, Wu X, Han T, Bu H, Tang S, Qian J, Shao P. Comprehensive investigation into cuproptosis in the characterization of clinical features, molecular characteristics, and immune situations of clear cell renal cell carcinoma. Front Immunol. 2022;13:948042.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Makhov P, Joshi S, Ghatalia P, Kutikov A, Uzzo RG, Kolenko VM. Resistance to systemic therapies in Clear Cell Renal Cell Carcinoma: mechanisms and management strategies. Mol Cancer Ther. 2018;17(7):1355–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wolf MM, Kimryn Rathmell W, Beckermann KE. Modeling clear cell renal cell carcinoma and therapeutic implications. Oncogene. 2020;39(17):3413–26.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bersanelli M, Buti S, Rizzo M. The need for new algorithms of treatment sequencing in clear-cell metastatic renal cell carcinoma. Expert Rev Anticancer Ther. 2021;21(4):401–12.

Article  CAS  PubMed  Google Scholar 

Chamoto K, Yaguchi T, Tajima M, Honjo T. Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1. Nat Rev Immunol. 2023;23(10):682–95.

Article  CAS  PubMed  Google Scholar 

Francis DM, Manspeaker MP, Schudel A, Sestito LF, O’Melia MJ, Kissick HT, Pollack BP, Waller EK, Thomas SN. Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy. Sci Transl Med 2020, 12(563).

Miao D, Margolis CA, Gao W, Voss MH, Li W, Martini DJ, Norton C, Bosse D, Wankowicz SM, Cullen D, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim MC, Borcherding N, Ahmed KK, Voigt AP, Vishwakarma A, Kolb R, Kluz PN, Pandey G, De U, Drashansky T, et al. CD177 modulates the function and homeostasis of tumor-infiltrating regulatory T cells. Nat Commun. 2021;12(1):5764.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tian J, Cheng C, Gao J, Fu G, Xu Z, Chen X, Wu Y, Jin B. POLD1 as a Prognostic Biomarker correlated with cell proliferation and Immune Infiltration in Clear Cell Renal Cell Carcinoma. Int J Mol Sci 2023, 24(7).

Obradovic A, Chowdhury N, Haake SM, Ager C, Wang V, Vlahos L, Guo XV, Aggen DH, Rathmell WK, Jonasch E, et al. Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages. Cell. 2021;184(11):2988–e30052916.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Msaouel P, Goswami S, Thall PF, Wang X, Yuan Y, Jonasch E, Gao J, Campbell MT, Shah AY, Corn PG, et al. A phase 1–2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Sci Transl Med. 2022;14(641):eabm6420.

Article  CAS  PubMed  Google Scholar 

Shi J, Liu J, Tu X, Li B, Tong Z, Wang T, Zheng Y, Shi H, Zeng X, Chen W et al. Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy. J Immunother Cancer 2022, 10(1).

Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, et al. Nivolumab plus Ipilimumab in Advanced Non-small-cell Lung Cancer. N Engl J Med. 2019;381(21):2020–31.

Article  CAS  PubMed  Google Scholar 

Eckel-Passow JE, Ho TH, Serie DJ, Cheville JC, Houston Thompson R, Costello BA, Dong H, Kwon ED, Leibovich BC, Parker AS. Concordance of PD-1 and PD-L1 (B7-H1) in paired primary and metastatic clear cell renal cell carcinoma. Cancer Med. 2020;9(3):1152–60.

Article  CAS  PubMed  Google Scholar 

Hong B, Cai L, Wang J, Liu S, Zhou J, Ma K, Zhang J, Zhou B, Peng X, Zhang N, et al. Differential expression of PD-L1 between sporadic and VHL-Associated Hereditary clear-cell renal cell carcinoma and its correlation with clinicopathological features. Clin Genitourin Cancer. 2019;17(2):97–104. e101.

Article  PubMed  Google Scholar 

Larrinaga G, Solano-Iturri JD, Errarte P, Unda M, Loizaga-Iriarte A, Perez-Fernandez A, Echevarria E, Asumendi A, Manini C, Angulo JC et al. Soluble PD-L1 is an independent prognostic factor in Clear Cell Renal Cell Carcinoma. Cancers (Basel) 2021, 13(4).

Ziblat A, Iraolagoitia XLR, Nunez SY, Torres NI, Secchiari F, Sierra JM, Spallanzani RG, Rovegno A, Secin FP, Fuertes MB, et al. Circulating and Tumor-infiltrating NK cells from Clear Cell Renal Cell Carcinoma patients exhibit a predominantly inhibitory phenotype characterized by overexpression of CD85j, CD45, CD48 and PD-1. Front Immunol. 2021;12:681615.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Q, Lu M, Zhang Z, Zhang R. Single-cell sequencing to identify six heat shock protein (HSP) genes-mediated progression subtypes of Clear Cell Renal Cell Carcinoma. Int J Gen Med. 2021;14:3761–73.

Article  PubMed  PubMed Central  Google Scholar 

Tang G, Guan H, Du Z, Yuan W. Comprehensive Analysis of the butyrate-metabolism-related gene signature in Tumor Microenvironment-infiltrating Immune cells in Clear Cell Renal Cell Carcinoma. Front Cell Dev Biol. 2022;10:816024.

Article  PubMed  PubMed Central  Google Scholar 

Zhang J, Yan A, Cao W, Shi H, Cao K, Liu X. Development and validation of a VHL-associated immune prognostic signature for clear cell renal cell carcinoma. Cancer Cell Int. 2020;20(1):584.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen K, Gao M, Dong W, Liu H, Lin Y, Xie Y, Zhong W, Chen J, Huang X, He W, et al. A novel lymphangiogenesis-related gene signature can predict prognosis and immunosuppressive microenvironment in patients with Clear Cell Renal Cell Carcinoma. Int J Med Sci. 2023;20(6):754–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu X, Xie W, Gong B, Fu B, Chen W, Zhou L, Luo L. Development and validation of a combined hypoxia- and metabolism-related prognostic signature to predict clinical prognosis and immunotherapy responses in clear cell renal cell carcinoma. Front Oncol. 2023;13:1162846.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen Y, Zhou X, Xie Y, Wu J, Li T, Yu T, Pang Y, Du W. Establishment of a Seven-Gene Signature Associated with CD8(+) T cells through the utilization of both single-cell and bulk RNA-Sequencing techniques in Clear Cell Renal Cell Carcinoma. Int J Mol Sci 2023, 24(18).

Chen J, Yao C, Qiao N, Ge Y, Li J, Lin Y, Yao S. Development and validation of a PBRM1-associated immune prognostic model for clear cell renal cell carcinoma. Cancer Med. 2021;10(19):6590–609.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gao X, Yang J, Chen Y. Identification of a four immune-related genes signature based on an immunogenomic landscape analysis of clear cell renal cell carcinoma. J Cell Physiol. 2020;235(12):9834–50.

Article  CAS  PubMed  Google Scholar 

Peng L, Liang J, Wang Q, Chen G. A DNA damage repair gene signature Associated with Immunotherapy Response and Clinical Prognosis in Clear Cell Renal Cell Carcinoma. Front Genet. 2022;13:798846.

Article  CAS  PubMed  PubM